BELLUS Health buys IP rights, banishes royalties; AbbVie gets confirmatory data on accelerated AML drug
→ Canada’s BELLUS Health $BLU has bagged the remaining IP rights for its BLU-5937 and related P2X3 antagonists. The deal scraps the tiered royalty payments that would have been due to adMare BioInnovations’ NEOMED Institute. AstraZeneca assigned that to them in 2012. BELLUS Health exchanged 7.3% of its equity for the rights.
→ Schrödinger $SDGR has expanded its computational research collaboration with AstraZeneca. Already working on small molecule drug discovery, they’ll now also be “focused on refining a biologics modeling solution with the aim of speeding up the development of antibody and protein-based therapeutic candidates.”
→ A year and a half after winning accelerated approval for Venclexta in acute myeloid leukemia on the basis of Phase I/II studies, AbbVie is out with positive Phase III results. The company did not release any specific numbers but said that the drug led to statistically significant improvements in overall survival and composite complete remission rate in treatment-naive patients. The biotech said they are reporting the results early at the recommendation of the independent data monitoring committee.
→ Micro-cap Celsion Corporation has been granted orphan designation for its lead compound GEN-1 in ovarian cancer.